secwatch.observer — SEC 8-K summary
======================================

Issuer:     KORU Medical Systems, Inc. (KRMD)
CIK:        0000704440
Form:       8-K
Filed at:   2023-03-08T23:59:59+00:00
Accession:  0001161697-23-000156
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KORU Medical reports 19% revenue growth in 2022, guides 17-20% growth for 2023
------------------------------------------------------------------------------

- Q4 2022 revenue $7.34M (+13.2% YoY); FY2022 revenue $27.9M (+18.8% YoY).
- FY2022 net loss $8.6M ($0.19 loss per share) vs $4.6M loss in 2021.
- Novel Therapies revenue grew 329.8% to $2.5M; Core business grew 11%.
- Cash $17.4M at year-end; 2023 guidance: revenue $32.5-$33.5M (17-20% growth), gross margins 58-60%, cash >$10M.
- Expects 6 new Novel Therapies collaborations and two 510(k) filings in H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/704440/000116169723000156/0001161697-23-000156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/704440/000116169723000156/form_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001161697-23-000156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer